Table 1.

Study Characteristics

Study	Intervention	# Treated	# Controls	Patient Population	Double Blinding
Groothuis 1993	RSV-IGIV 750 mg/kg	81	89	Premature, CLD, CHD	No
PREVENT 1997	RSV-IGIV 750 mg/kg	250	260	Premature, CLD	Yes
Simoes 1998	RSV-IGIV 750 mg/kg	202	214	CHD	No
Subramanian 1998	Palivizumab 15 mg/kg	22	20	Premature, CLD	Yes
IMPACT 1998	Palivizumab 15 mg/kg	1002	500	Premature, CLD	Yes
Feltes 2003	Palivizumab 15 mg/kg	639	648	CHD	Yes